Qiagen (QGEN) Tops Q1 EPS by 6c

Go back to Qiagen (QGEN) Tops Q1 EPS by 6c

QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups

February 7, 2023 4:05 PM EST

Q4 2022: Net sales of $498 million (-14% at actual rates, -9% at constant exchange rates, CER); diluted EPS of $0.39 and adjusted diluted EPS of $0.53 Net sales at CER of $531 million vs. outlook for at least $520 million CER, adjusted diluted EPS of $0.55 CER vs. outlook for at least $0.50 CER 15% CER growth in non-COVID product portfolio to $432 million Full-year 2022: Net sales decline 5% (0% CER) to $2.14 billion; diluted EPS of $1.84 and adjusted diluted EPS of $2.38 ($2.46 CER) - results exceed outlook 14% CER growth in non-COVID product portfolio to... More